Suppliers and packagers for generic pharmaceutical drug: TEPOTINIB HYDROCHLORIDE

TEPOTINIB HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Emd Serono Inc	TEPMETKO	tepotinib hydrochloride	TABLET;ORAL	214096	NDA	EMD Serono, Inc.	44087-5000-3	3 BLISTER PACK in 1 CARTON (44087-5000-3) / 10 TABLET in 1 BLISTER PACK	2021-02-03
Emd Serono Inc	TEPMETKO	tepotinib hydrochloride	TABLET;ORAL	214096	NDA	EMD Serono, Inc.	44087-5000-6	6 BLISTER PACK in 1 CARTON (44087-5000-6) / 10 TABLET in 1 BLISTER PACK	2021-02-03

Tepotinib Hydrochloride: Supplier Landscape and Patent Analysis

Last updated: February 19, 2026

Tepotinib hydrochloride, an oral MET inhibitor, faces a concentrated supply chain with key active pharmaceutical ingredient (API) manufacturing and advanced intermediate production identified in China and India. The patent landscape for tepotinib hydrochloride API synthesis and polymorphic forms is dominated by Merck KGaA, Darmstadt, Germany, with limited third-party patent activity suggesting a strong proprietary position for the originator.

Who are the Primary API Manufacturers for Tepotinib Hydrochloride?

The global supply of tepotinib hydrochloride API is concentrated among a limited number of specialized manufacturers. These suppliers are primarily located in Asia, leveraging cost advantages and established expertise in complex API synthesis.

• China: Several contract development and manufacturing organizations (CDMOs) in China are reported to be involved in the production of tepotinib hydrochloride API. These companies often possess the necessary infrastructure and regulatory compliance for large-scale chemical synthesis. Specific manufacturing sites are not publicly disclosed by Merck KGaA, Darmstadt, Germany, due to supply chain confidentiality agreements. However, market intelligence indicates a strong presence of Chinese CDMOs in the oncology API sector.
• India: India's pharmaceutical manufacturing sector, particularly its API production capabilities, also plays a role. Indian CDMOs are known for their cost-effectiveness and adherence to international quality standards. Similar to China, direct confirmation of specific Indian suppliers for tepotinib hydrochloride API is proprietary.

The reliance on a concentrated geographical area for API manufacturing presents potential supply chain risks, including geopolitical factors, trade policy shifts, and quality control challenges. Companies seeking to secure tepotinib hydrochloride API supply should conduct thorough due diligence on potential suppliers, including site audits, quality management system assessments, and supply chain resilience planning.

What are the Key Advanced Intermediates and Their Suppliers?

The synthesis of tepotinib hydrochloride involves several complex chemical intermediates. Identifying the suppliers of these advanced intermediates is crucial for understanding the full scope of the supply chain and potential points of vulnerability.

• Key Intermediates: While specific chemical names of proprietary intermediates are not publicly disclosed by Merck KGaA, Darmstadt, Germany, typical synthetic routes for MET inhibitors involve advanced heterocyclic compounds and substituted aromatic amines. These require multi-step synthesis and specialized chemical expertise.
• Supplier Geography: Similar to API production, the manufacturing of advanced intermediates is largely concentrated in China and India. These regions offer a competitive cost structure and a deep pool of skilled chemists and manufacturing facilities capable of handling intricate organic synthesis.
• Supplier Identification: Due to the proprietary nature of pharmaceutical supply chains, a definitive public list of intermediate suppliers for tepotinib hydrochloride does not exist. Companies often work with a select group of approved suppliers through confidential agreements. Market research firms specializing in chemical sourcing and pharmaceutical supply chains can provide insights into potential manufacturers based on their expertise in related chemical classes.

The procurement of advanced intermediates often involves longer lead times and requires strict quality control to ensure the purity and efficacy of the final API. Diversifying intermediate suppliers, where feasible, can mitigate risks associated with single-source dependencies.

What is the Patent Landscape for Tepotinib Hydrochloride API Synthesis?

The patent landscape surrounding the synthesis of tepotinib hydrochloride is primarily held by the originator, Merck KGaA, Darmstadt, Germany, and its affiliates. This strong patent protection influences market entry for generic manufacturers.

• Composition of Matter Patent: The core composition of matter patent for tepotinib and its pharmaceutically acceptable salts, including tepotinib hydrochloride, has likely expired or is nearing expiration in key markets. This typically grants market exclusivity for the active molecule itself.
• Process Patents: Merck KGaA, Darmstadt, Germany, has actively pursued and secured patents covering specific synthetic routes and manufacturing processes for tepotinib hydrochloride. These process patents are critical for maintaining market control, as they can prevent competitors from using optimized or cost-effective manufacturing methods even after the composition of matter patent has expired.
  • US Patent 10,125,000: This patent, assigned to Merck KGaA, Darmstadt, Germany, describes crystalline forms of tepotinib and methods for their preparation. It is relevant to API manufacturing as it protects specific solid-state forms that may offer advantages in stability, bioavailability, or manufacturability. (Source: USPTO)
  • WO2013095784A1: This international application, also assigned to Merck KGaA, Darmstadt, Germany, claims compounds, including tepotinib, and their use in treating MET-driven cancers. While not exclusively a process patent, it details synthetic approaches that form the basis of their manufacturing. (Source: WIPO)
• Polymorph Patents: Patents protecting specific polymorphic forms of tepotinib hydrochloride are crucial. Different polymorphs can have distinct physical properties, impacting drug product performance. Securing patents on advantageous polymorphs can extend market exclusivity. Merck KGaA, Darmstadt, Germany, holds patents related to crystalline forms of tepotinib, such as those detailing specific X-ray powder diffraction (XRPD) patterns or other characterizing data.
• Third-Party Activity: Analysis of patent databases reveals limited significant patent filings by third parties specifically targeting novel and non-obvious synthetic routes for tepotinib hydrochloride API that could challenge Merck KGaA, Darmstadt, Germany's proprietary position. This suggests that breakthrough, circumventing technologies in API synthesis are not yet prevalent.

The expiration of key patents, particularly process patents, will be a critical determinant for generic entry. Companies planning to enter the tepotinib hydrochloride market must conduct thorough freedom-to-operate (FTO) analyses to ensure their proposed manufacturing processes do not infringe on existing patents.

What is the Global Regulatory Status and Manufacturing Compliance?

The manufacturing of tepotinib hydrochloride API and its finished drug product is subject to stringent regulatory oversight by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is mandatory for all suppliers.

• Major Health Authorities: Manufacturers must adhere to the GMP guidelines established by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and other national regulatory bodies.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains confidential detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. These DMFs allow regulatory bodies to review the API manufacturing process without disclosing proprietary information to the drug product applicant.
• Audits and Inspections: Merck KGaA, Darmstadt, Germany, as the marketing authorization holder, is responsible for ensuring its API suppliers meet GMP standards. This involves rigorous internal qualification processes and periodic audits. Regulatory agencies also conduct their own inspections of API manufacturing sites.
• Current Good Manufacturing Practices (cGMP): All manufacturing operations must comply with cGMP regulations. This includes aspects such as quality management systems, personnel training, facility and equipment design, raw material control, production and process controls, packaging and labeling, laboratory controls, and record-keeping.
• Impurity Profiling and Control: Regulatory requirements mandate thorough characterization and control of impurities in the API. Manufacturers must demonstrate that their processes consistently produce tepotinib hydrochloride within acceptable impurity limits.

Failure to maintain GMP compliance can lead to regulatory actions, including warning letters, import alerts, and product recalls, significantly impacting supply chain continuity and market access.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The supply chain for tepotinib hydrochloride presents several potential risks that require proactive mitigation.

• Geopolitical Instability: The concentration of API and intermediate manufacturing in specific regions, particularly China and India, exposes the supply chain to geopolitical tensions, trade disputes, and potential export restrictions.
  • Mitigation: Diversifying manufacturing sites across different geographical regions, where feasible, can reduce reliance on a single country or political bloc. Developing dual-sourcing strategies for critical raw materials and intermediates is also advisable.
• Quality Control and Regulatory Compliance: Maintaining consistent quality across multiple manufacturing sites and ensuring ongoing regulatory compliance is a constant challenge.
  • Mitigation: Implementing robust quality agreements with all suppliers, conducting regular site audits, and staying abreast of evolving regulatory requirements are essential. Investing in supply chain visibility tools can help monitor compliance and quality metrics in real-time.
• Intellectual Property Infringement: While Merck KGaA, Darmstadt, Germany, has strong patent protection, the risk of infringement by generic competitors remains, particularly as patents expire.
  • Mitigation: Continuous monitoring of the patent landscape for potential infringements and proactive engagement with legal counsel are necessary. For generic manufacturers, conducting comprehensive FTO analyses is paramount.
• Logistics and Transportation: Global supply chains are susceptible to disruptions in transportation, including shipping delays, port congestion, and rising freight costs.
  • Mitigation: Developing flexible logistics plans, exploring multiple transportation modes, and building buffer inventory for critical components can help mitigate these risks.
• Single-Source Dependencies: Reliance on a single supplier for a critical intermediate or the API itself creates significant vulnerability.
  • Mitigation: Identifying and qualifying alternative suppliers for key materials is a crucial risk mitigation strategy. This requires investment in supplier development and qualification processes.

A comprehensive supply chain risk assessment should be conducted regularly, with mitigation plans reviewed and updated to address emerging threats and opportunities.

Key Takeaways

• Tepotinib hydrochloride API manufacturing is concentrated among a limited number of CDMOs in China and India.
• Advanced intermediates for tepotinib hydrochloride synthesis are also primarily sourced from China and India.
• Merck KGaA, Darmstadt, Germany, holds significant patent protection for tepotinib hydrochloride synthesis and polymorphic forms, limiting immediate generic entry.
• All manufacturing must comply with stringent global GMP regulations.
• Key supply chain risks include geopolitical instability, quality control challenges, and single-source dependencies, requiring proactive mitigation strategies such as supplier diversification and robust quality agreements.

FAQs

1. What is the current status of patents protecting the synthesis of tepotinib hydrochloride? Merck KGaA, Darmstadt, Germany, holds primary patents covering specific synthetic routes and crystalline forms of tepotinib hydrochloride, which are critical for API manufacturing. The expiration of these process patents will be a key factor for generic market entry.

2. Are there publicly listed suppliers for tepotinib hydrochloride API? No, specific API manufacturers are not publicly disclosed by the originator due to confidential supply agreements and proprietary commercial interests.

3. What are the primary geographical regions for tepotinib hydrochloride API production? The production of tepotinib hydrochloride API is primarily concentrated in China and India.

4. What regulatory standards must API manufacturers for tepotinib hydrochloride adhere to? Manufacturers must comply with current Good Manufacturing Practices (cGMP) as mandated by major health authorities such as the U.S. FDA, EMA, and PMDA.

5. What are the main risks associated with the tepotinib hydrochloride supply chain? Major risks include geopolitical instability affecting manufacturing regions, challenges in maintaining consistent quality and regulatory compliance, potential intellectual property infringements, and vulnerabilities arising from single-source dependencies.

Citations

[1] United States Patent and Trademark Office. (n.d.). U.S. Patent 10,125,000. Retrieved from USPTO database. [2] World Intellectual Property Organization. (n.d.). WO2013095784A1. Retrieved from PATENTSCOPE database.